Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5215396 | 0.83 | HTR1A (0.41) | HTR1BRAB9AHTR1ASLC6A4SMN1; SMN2 | |
| SCHEMBL4313222 | 0.83 | HTR1A (0.41) | HTR1BKDM4ETP53MAPK1RAB9A | |
| SCHEMBL7834298 | 0.83 | HTR1A (0.41) | HTR1BHTR1ASLC6A4HPGDTRPA1 | |
| SCHEMBL3789397 | 0.83 | MCHR1 (0.46) | HTR1BHTR1ASLC6A4 | |
| SCHEMBL3795511 | 0.81 | MCHR1 (0.48) | HTR1BHTR1ASLC6A4 | |
| SCHEMBL7688315 | 0.79 | SLC6A4 (0.42) | HTR1BRAB9AHTR1ASLC6A4KCNA3 | |
| SCHEMBL3796715 | 0.79 | ADORA3 (0.49) | KDM4E | |
| SCHEMBL11811685 | 0.79 | HTR1A (0.38) | HTR1BMAPK1RAB9AHTR1ASLC6A4 | |
| SCHEMBL7928500 | 0.78 | NCF1 (0.40) | KDM4EMAPK1HTR1ASLC6A4NCF1 | |
| SCHEMBL23544480 | 0.77 | GAA (0.45) | KDM4EMAPK1HTR1ASLC6A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082582-A1 | Process For Preparing [2-(2,3- Dihydrobenzofuran - Or Benzofuran-7-Yloxy)Ethyl]-(3 -Cyclopent-1-Ylbenzyl)Amine Derivatives and Synthesis Intermediate | PIERRE FABRE MEDICAMENT (FR) | 2009-03-26 | — | — | US | disclosed |
| EP-1996570-A1 | PROCESS FOR PREPARING [2-(2,3-DIHYDROBENZOFURAN- OR BENZOFURAN-7-YLOXY)ETHYL]-(3-CYCLOPENT-1-YLBENZYL)AMINE DERIVATIVES AND SYNTHESIS INTERMEDIATE | Pierre Fabre Médicament S.A. (FR) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007104872-A1 | PROCESS FOR PREPARING [2-(2,3-DIHYDROBENZOFURAN- OR BENZOFURAN-7-YLOXY)ETHYL]-(3-CYCLOPENT-1-YLBENZYL)AMINE DERIVATIVES AND SYNTHESIS INTERMEDIATE | PIERRE FABRE MEDICAMENT (FR) | 2007-09-20 | — | — | WO | disclosed |
| US-7235568-B2 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-06-26 | — | — | US | disclosed |
| US-7163957-B2 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-01-16 | — | — | US | disclosed |
| US-20060264471-A1 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derviatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2006-11-23 | — | — | US | disclosed |
| EP-1551821-B1 | 3-(CYCLOPENTEN-1-YL)-BENZYL- OR 3-(CYCLOPENTEN-1-YL)-HETEROARYLMETHYL-AMINE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING SCHIZOPHRENIA | PF MEDICAMENT (FR) | 2006-05-17 | — | — | EP | disclosed |
| US-20060014827-A1 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-1551821-A1 | 3-(CYCLOPENTEN-1-YL)-BENZYL- OR 3-(CYCLOPENTEN-1-YL)-HETEROARYLMETHYL-AMINE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING SCHIZOPHRENIA | PIERRE FABRE MEDICAMENT (FR) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035561-A1 | 3-(CYCLOPENTEN-1-YL)-BENZYL- OR 3-(CYCLOPENTEN-1-YL)-HETEROARYLMETHYL-AMINE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING SCHIZOPHRENIA | PIERRE FABRE MEDICAMENT (FR) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264471-A1 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derviatives and use thereof as medicines for treating schizophrenia | CNR2, CNR1, DBH | HTR1B 98/4885KDM4E 2093/4885TP53 4546/4885 |
| US-20090082582-A1 | Process For Preparing [2-(2,3- Dihydrobenzofuran - Or Benzofuran-7-Yloxy)Ethyl]-(3 -Cyclopent-1-Ylbenzyl)Amine Derivatives and Synthesis Intermediate | TAC3, NCAPD3, PAH | HTR1B 1581/4885KDM4E 3219/4885TP53 4819/4885 |
| US-20060014827-A1 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | CHRNA3, CHRNB3, CNR2 | HTR1B 253/4885KDM4E 3078/4885TP53 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.